Is SPTX or IKT more profitable?

Seaport Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Seaport Therapeutics N/A N/A N/A Inhibikase Therapeutics N/A -42.80% -40.58%

Do analysts rate CALT or IKT?

Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 116.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Inhibikase Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.00

Is IKT or ANRO more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -42.80% -40.58% Alto Neuroscience N/A -46.46% -39.09%

Inhibikase Therapeutics (IKT) Competitors

$2.50 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 0.00 (-0.20%)

As of 04:10 PM Eastern

Compare

IKT vs. SPTX, EYPT, CALT, CRON, and ANRO

Should you buy Inhibikase Therapeutics stock or one of its competitors? Inhibikase Therapeutics's main competitors and comparable companies include Seaport Therapeutics (SPTX), Eyepoint Pharmaceuticals (EYPT), Calliditas Therapeutics AB (publ) (CALT), Cronos Group (CRON), and Alto Neuroscience (ANRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Inhibikase Therapeutics compare to Seaport Therapeutics?

Seaport Therapeutics (NASDAQ:SPTX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Seaport Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Seaport Therapeutics currently has a consensus price target of $38.40, suggesting a potential upside of 55.28%. Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 116.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Inhibikase Therapeutics has higher revenue and earnings than Seaport Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Inhibikase Therapeutics	$260K	1,341.73	-$48.26M	-$0.43	N/A

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Seaport Therapeutics had 5 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 5 mentions for Seaport Therapeutics and 0 mentions for Inhibikase Therapeutics. Seaport Therapeutics' average media sentiment score of 0.36 beat Inhibikase Therapeutics' score of 0.00 indicating that Seaport Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Seaport Therapeutics	Neutral
Inhibikase Therapeutics	Neutral

Summary

Inhibikase Therapeutics beats Seaport Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Eyepoint Pharmaceuticals had 19 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 19 mentions for Eyepoint Pharmaceuticals and 0 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 beat Eyepoint Pharmaceuticals' score of -0.02 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eyepoint Pharmaceuticals	Neutral
Inhibikase Therapeutics	Neutral

Eyepoint Pharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Eyepoint Pharmaceuticals currently has a consensus price target of $28.11, indicating a potential upside of 461.10%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 116.00%. Given Eyepoint Pharmaceuticals' higher probable upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Inhibikase Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Inhibikase Therapeutics' return on equity of -42.80% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Inhibikase Therapeutics has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$2.79M	154.92	-$231.96M	-$3.74	N/A
Inhibikase Therapeutics	$260K	1,341.73	-$48.26M	-$0.43	N/A

Summary

Inhibikase Therapeutics beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 116.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Inhibikase Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Inhibikase Therapeutics' return on equity of -42.80% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Inhibikase Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Inhibikase Therapeutics	$260K	1,341.73	-$48.26M	-$0.43	N/A

In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Inhibikase Therapeutics'average media sentiment score.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Inhibikase Therapeutics	Neutral

Summary

Inhibikase Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Cronos Group?

Inhibikase Therapeutics (NASDAQ:IKT) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Cronos Group has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,341.73	-$48.26M	-$0.43	N/A
Cronos Group	$146.59M	8.88	-$9.45M	$0.20	17.55

Inhibikase Therapeutics currently has a consensus price target of $5.40, suggesting a potential upside of 116.00%. Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 34.47%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Inhibikase Therapeutics is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Cronos Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cronos Group has a net margin of 39.08% compared to Inhibikase Therapeutics' net margin of 0.00%. Cronos Group's return on equity of 4.85% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Cronos Group	39.08%	4.85%	4.62%

In the previous week, Cronos Group had 6 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Cronos Group and 0 mentions for Inhibikase Therapeutics. Cronos Group's average media sentiment score of 0.46 beat Inhibikase Therapeutics' score of 0.00 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
Cronos Group	Neutral

Inhibikase Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 7.8% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cronos Group beats Inhibikase Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Alto Neuroscience?

Inhibikase Therapeutics (NASDAQ:IKT) and Alto Neuroscience (NYSE:ANRO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Inhibikase Therapeutics' return on equity of -42.80% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Alto Neuroscience	N/A	-46.46%	-39.09%

Inhibikase Therapeutics has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,341.73	-$48.26M	-$0.43	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Alto Neuroscience had 19 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 19 mentions for Alto Neuroscience and 0 mentions for Inhibikase Therapeutics. Alto Neuroscience's average media sentiment score of 0.95 beat Inhibikase Therapeutics' score of 0.00 indicating that Alto Neuroscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
Alto Neuroscience	Positive

Inhibikase Therapeutics presently has a consensus price target of $5.40, suggesting a potential upside of 116.00%. Alto Neuroscience has a consensus price target of $37.25, suggesting a potential upside of 2.91%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Inhibikase Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Inhibikase Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Summary

Inhibikase Therapeutics beats Alto Neuroscience on 9 of the 15 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IKT vs. The Competition

Export

Metric	Inhibikase Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$348.85M	$12.55B	$7.31B	$12.77B
Dividend Yield	N/A	2.61%	2.54%	10.78%
P/E Ratio	-5.81	778.14	271.23	24.19
Price / Sales	1,341.73	961.13	696.77	129.00
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	1.09	10.58	11.33	6.52
Net Income	-$48.26M	$2.80B	$3.46B	$347.63M
7 Day Performance	4.17%	3.95%	3.26%	1.60%
1 Month Performance	7.30%	6.54%	8.85%	5.27%
1 Year Performance	N/A	8.76%	27.68%	17.87%

Inhibikase Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IKT Inhibikase Therapeutics	1.5302 of 5 stars	$2.50 flat	$5.40 +116.0%	N/A	$348.85M	$260K	N/A	6
SPTX Seaport Therapeutics	2.9261 of 5 stars	$24.40 +0.7%	$38.40 +57.4%	N/A	$1.30B	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	2.3525 of 5 stars	$4.87 -67.0%	$40.33 +728.2%	-58.8%	$1.27B	$31.37M	N/A	120	Analyst Upgrade Gap Up High Trading Volume
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
CRON Cronos Group	1.6428 of 5 stars	$3.15 +0.3%	$2.30 -27.0%	+31.2%	$1.16B	$146.59M	15.75	450	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IKT) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibikase Therapeutics (IKT) Competitors

IKT vs. SPTX, EYPT, CALT, CRON, and ANRO

How does Inhibikase Therapeutics compare to Seaport Therapeutics?

Summary

How does Inhibikase Therapeutics compare to Eyepoint Pharmaceuticals?

Summary

How does Inhibikase Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Inhibikase Therapeutics compare to Cronos Group?

Summary

How does Inhibikase Therapeutics compare to Alto Neuroscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibikase Therapeutics (IKT) Competitors

IKT vs. SPTX, EYPT, CALT, CRON, and ANRO

How does Inhibikase Therapeutics compare to Seaport Therapeutics?

Is SPTX or IKT more profitable?

Do analysts prefer SPTX or IKT?

Which has better earnings and valuation, SPTX or IKT?

Do insiders and institutionals have more ownership in SPTX or IKT?

Does the media favor SPTX or IKT?

Summary

How does Inhibikase Therapeutics compare to Eyepoint Pharmaceuticals?

Do insiders & institutionals believe in EYPT or IKT?

Does the media prefer EYPT or IKT?

Which has more volatility & risk, EYPT or IKT?

Do analysts recommend EYPT or IKT?

Is EYPT or IKT more profitable?

Which has better earnings & valuation, EYPT or IKT?

Summary

How does Inhibikase Therapeutics compare to Calliditas Therapeutics AB (publ)?

Do analysts rate CALT or IKT?

Is CALT or IKT more profitable?

Which has more volatility & risk, CALT or IKT?

Do institutionals & insiders hold more shares of CALT or IKT?

Which has better earnings and valuation, CALT or IKT?

Does the media prefer CALT or IKT?

Summary

How does Inhibikase Therapeutics compare to Cronos Group?

Which has stronger valuation and earnings, IKT or CRON?

Do analysts rate IKT or CRON?

Is IKT or CRON more profitable?

Does the media prefer IKT or CRON?

Which has more volatility & risk, IKT or CRON?

Do insiders and institutionals hold more shares of IKT or CRON?

Summary

How does Inhibikase Therapeutics compare to Alto Neuroscience?

Is IKT or ANRO more profitable?

Which has preferable earnings & valuation, IKT or ANRO?

Do institutionals & insiders hold more shares of IKT or ANRO?

Does the media prefer IKT or ANRO?

Do analysts prefer IKT or ANRO?

Which has more volatility and risk, IKT or ANRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools